Core Viewpoint - The orthopedic industry is facing issues of high sales expenses and shrinking R&D investment, with major companies like Dabo Medical having sales expense ratios above the industry average [1] Group 1: Company Developments - Dabo Medical has recently made a new investment, fully acquiring Maikoste (Xiamen) Medical Equipment Co., Ltd. with a registered capital of 5 million yuan, focusing on professional technical services [1] Group 2: Stock Performance - Dabo Medical's stock price decreased from 50.14 yuan to 48.03 yuan over the past week, reflecting a decline of 2.66% and a volatility of 6.49%; on February 11, the stock fell by 1.58% with a net outflow of 10.377 million yuan [2] - As of February 12, the stock price slightly increased by 0.36% to 48.03 yuan, with a turnover rate of 0.60% and a trading volume of 82.96 million yuan; technical indicators suggest a downward trend [2] Group 3: Financial Performance - Dabo Medical expects a net profit attributable to shareholders for the year 2025 to be between 580 million yuan and 610 million yuan, representing a year-on-year growth of 62.55% to 70.96%; the non-recurring net profit is projected to grow by 59.42% to 69.93% [3] - The primary drivers of this growth are focused on core business, product innovation, and the advancement of international strategies, with a revenue of 1.876 billion yuan in the first three quarters of 2025, marking a year-on-year increase of 22.69% [3] Group 4: Institutional Insights - Institutions predict a net profit growth rate of 50.67% for 2025, with a slowdown to 16.88% in 2026; current institutional ratings are neutral, and the fund holding ratio is low at 0.88%, indicating moderate market attention [4]

Core Viewpoint - The orthopedic industry is facing scrutiny due to commercial bribery cases, while major companies are reporting significant revenue and profit growth for 2025, highlighting a contrast between industry recovery and ongoing issues of high sales expenses and unethical practices [2][6][8]. Group 1: Bribery Cases and Industry Impact - The National Healthcare Security Administration has reported significant bribery cases in the orthopedic field, with kickback rates reaching up to 40% [2][3]. - In a case involving a hospital director, illegal kickbacks totaled 2.72 million yuan, with a supplier paying 35% of the total supply as a monthly kickback [4]. - Another case revealed a hospital official receiving 3.66 million yuan in bribes over ten years, with kickback rates between 20% and 40% for various orthopedic devices [5]. Group 2: Financial Performance of Companies - Major orthopedic companies like Spring Medical, Dabo Medical, and Kelly Tai are forecasting significant revenue and profit increases for 2025, with some companies expecting profit growth exceeding 300% [2][6][7]. - The orthopedic consumables sector saw a 17% year-on-year revenue growth in the first three quarters of 2025, with net profit increasing by 81% [6][16]. - Spring Medical anticipates a net profit of 245 to 288 million yuan for 2025, representing a year-on-year increase of 96.01% to 130.41% [6][16]. Group 3: Sales Expenses and Challenges - Despite positive financial forecasts, high sales expenses remain a significant concern, with some companies' sales expense ratios exceeding the industry average [8][18]. - For instance, Dabo Medical's sales expense ratio was approximately 26.7%, indicating elevated marketing costs within the orthopedic sector [18]. - The ongoing high sales expenses are squeezing companies' research and development budgets, with reductions in R&D spending reported by several firms [19].

Core Viewpoint - The stock of Dabo Medical (002901) has shown a recent increase in price and positive financial performance, indicating potential investment opportunities in the medical device sector. Group 1: Stock Performance - As of February 5, 2026, Dabo Medical closed at 50.14 yuan, up 1.62% with a turnover rate of 0.61% and a trading volume of 17,600 shares, resulting in a transaction value of 88.34 million yuan [1] - On February 5, 2026, the net inflow of main funds was 418,700 yuan, accounting for 0.47% of the total transaction value, while retail investors saw a net inflow of 1.17 million yuan, representing 1.33% of the total [1] Group 2: Financing and Margin Trading - On February 5, 2026, the financing buy amounted to 7.38 million yuan, while financing repayment was 9.08 million yuan, resulting in a net repayment of 1.70 million yuan [1] - The total financing balance on February 5, 2026, was 155 million yuan, with a margin trading balance of 155 million yuan [2] Group 3: Financial Metrics and Industry Comparison - Dabo Medical's total market capitalization is 20.76 billion yuan, with a net profit of 425 million yuan, which is significantly higher than the industry average of 208 million yuan [4] - The company reported a gross margin of 71.23% and a net profit margin of 23.92%, both of which are above the industry averages of 50.55% and 9.59%, respectively [4] - For the first three quarters of 2025, Dabo Medical's main revenue was 1.88 billion yuan, a year-on-year increase of 22.69%, and the net profit attributable to shareholders was 425 million yuan, up 77.03% year-on-year [4]

Core Viewpoint - Dabo Medical (002901) shows a positive trend in stock performance and financial metrics, indicating potential growth opportunities in the medical device industry. Financial Performance - As of February 3, 2026, Dabo Medical's stock closed at 49.75 yuan, up 1.12%, with a trading volume of 18,500 lots and a transaction value of 91.64 million yuan [1] - For the first three quarters of 2025, the company reported a main revenue of 1.876 billion yuan, a year-on-year increase of 22.69%, and a net profit of 425 million yuan, up 77.03% year-on-year [2] - The company's gross profit margin stands at 71.23%, significantly higher than the industry average of 50.55% [2] Market Position - Dabo Medical has a total market capitalization of 20.597 billion yuan, ranking 12th in the medical device industry [2] - The company has a price-to-earnings ratio (P/E) of 36.38, which is lower than the industry average of 97.37, indicating a potentially undervalued stock [2] - The return on equity (ROE) is 12.83%, placing the company 8th in the industry, which reflects strong profitability compared to peers [2] Recent Trading Activity - On February 3, 2026, the net outflow of main funds was 2.7838 million yuan, while retail investors saw a net inflow of 1.1964 million yuan [1] - Over the past five days, the stock has experienced fluctuations in fund flows, with notable retail interest despite some institutional selling [1]

Group 1 - The company, Dabo Medical, held its fourth board meeting on February 2, 2026, to discuss the election of members and chairpersons for various specialized committees [1] - The meeting was conducted both in-person and via communication methods, indicating a flexible approach to governance [1] Group 2 - The article discusses Kevin Walsh's new policy concept, which aims to balance monetary easing and tightening, utilizing AI to manage inflation [1] - Walsh's approach includes a rejection of being a major buyer of U.S. Treasury bonds, suggesting a shift in investment strategy [1]

证券代码：002901 证券简称：大博医疗 公告编号：2026-010 大博医疗科技股份有限公司 关于董事会完成换届选举暨聘任高级管理人员、 董事会秘书及证券事务代表的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 大博医疗科技股份有限公司（以下简称"公司"）于 2026 年 2 月 2 日召开 2026 年第一次临时股东会，审议通过了《关于选举第四届董事会独立董事的议 案》《关于选举第四届董事会非独立董事的议案》。同日，公司召开了第四届董 事会第一次会议，审议通过了《关于选举公司第四届董事会董事长及副董事长的 议案》《关于选举公司第四届董事会各专门委员会委员及主任委员的议案》《关 于延期聘任公司总经理的议案》《关于聘任公司副总经理的议案》《关于聘任公 司财务总监的议案》《关于聘任公司董事会秘书的议案》《关于聘任公司证券事 务代表的议案》。现将公司董事会换届选举暨聘任高级管理人员、董事会秘书及 证券事务代表的具体情况公告如下： 一、公司第四届董事会组成情况 公司第四届董事会由7名董事组成，其中非独立董事3名，职工代表董事1名， 独立董事3名，具体成员如下 ...

证券代码：002901 证券简称：大博医疗 公告编号：2026-009 大博医疗科技股份有限公司 第四届董事会第一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 大博医疗科技股份有限公司（以下简称"公司"）第四届董事会第一次会议 于 2026 年 2 月 2 日以现场及通讯方式召开。在公司 2026 年第一次临时股东会选 举第四届董事会成员后，经全体董事一致同意豁免会议通知时间要求，现场发出 会议通知。本次会议应参加董事 7 名，实际参加董事 7 名，本次会议的召开符合 《公司法》《公司章程》等法律法规的规定，合法有效。 本次会议由董事长林志雄先生主持，与会董事就会议议案进行了审议、表决， 形成了如下决议： 一、会议以7票赞成、0票反对、0票弃权的表决结果审议通过了《关于选举 公司第四届董事会董事长及副董事长的议案》。 经审议，同意选举林志雄先生为公司第四届董事会董事长，林志军先生为副 董事长，任期三年，自本次董事会审议通过之日起至第四届董事会任期届满之日 止。（简历详见附件） 二、会议以7票赞成、0票反对、0票弃权的表决结果审议通过了《关于选 ...

Core Viewpoint - Dabo Medical (002901) experienced a stock price decline of 3.77% to 49.2 yuan as of February 2, 2026, with a total market capitalization of 20.37 billion yuan [1]. Group 1: Stock Performance - The stock opened at 51.31 yuan, reached a high of 51.31 yuan, and a low of 49.15 yuan on the same day [1]. - The trading volume was 1.43 million yuan, with a turnover rate of 0.99% [1]. Group 2: Shareholder Meeting - Dabo Medical held its first extraordinary general meeting of shareholders for 2026 on February 2, 2026, using a combination of on-site voting and online voting [1]. - A total of 32 shareholders and their proxies attended the meeting, representing 348,862,370 shares with voting rights, accounting for 85.3454% of the total voting shares [1]. Group 3: Board Elections - The meeting approved the election of independent directors and non-independent directors for the fourth board of directors [1]. - The elected independent directors are Xiao Wei, Wei Zhi Hua, and Fan Wei Wei, while Lin Zhi Xiong, Lin Zhi Jun, and Wang Shu Lin were elected as non-independent directors [1]. - The term for the fourth board of directors is three years, starting from the date of approval by the shareholders' meeting [1].

大博医疗科技股份有限公司 关于选举第四届董事会职工代表董事的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 大博医疗科技股份有限公司（以下简称"公司"）第三届董事会任期已届满， 根据《中华人民共和国公司法》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等法律法规、规范性文件及《公司章程》的有关 规定，公司董事会由 7 名董事组成，其中 1 名为职工代表董事，由公司职工代表 大会选举产生。 为进一步完善公司治理结构，保证公司董事会规范运作，公司于近日召开职 工代表大会。经全体与会职工代表审议，一致同意选举阮东阳先生为公司第四届 董事会职工代表董事（简历附后）。阮东阳先生将与公司 2026 年第一次临时股 东会选举产生的董事共同组成公司第四届董事会，任期与第四届董事会任期一致。 证券代码：002901 证券简称：大博医疗 公告编号：2026-008 职工代表董事简历 阮东阳先生：1973 年 12 月出生，中国国籍，无境外居留权。大学学历。1994 年 11 月至 2015 年 11 月，阮东阳于南靖县林业局任资源员。2008 年 ...

福建信实律师事务所 关于 大博医疗科技股份有限公司 2026 年第一次临时股东会 之 法 律 意 见 书 福建信实律师事务所 中国·厦门市思明区湖滨南路 334 号二轻大厦 9 层 电话/Tel：86 592 590 9988 传真/Fax：86 592 590 9989 www.lhxs.com 厦门湖滨南路 334 号二轻大厦 9 楼 邮编 361001 电话 +86 592 5909988 传真 +86 592-5909989 www.lhxs.com 福建信实律师事务所 关于大博医疗科技股份有限公司 2026 年第一次临时股东会之 法 律 意 见 书 (2026)闽信实律书字 0043 号 致：大博医疗科技股份有限公司 福建信实律师事务所(以下简称"本所")受大博医疗科技股份有限公司(以下 简称"公司")的委托，指派许智明律师、吴上烁律师 (以下简称"本所律师") 出席公司于2026年2月2日召开的公司2026年第一次临时股东会(以下简称"本次 股东会")。本所律师根据《中华人民共和国公司法》(以下简称"《公司法》")、 《中华人民共和国证券法》(以下简称"《证券法》")、《上市公司股东会规则》(以 ...